NeoGenomics is transitioning from a commodity diagnostic provider to a comprehensive precision oncology platform. Read why ...

NeoGenomics (NEO) on Monday said for the fourth quarter of 2025, it expects to report total revenue of approximately $190 million, representing year-over-year growth of 11%. For the full-year 2025, ...

Long-Range Plan reflects 12-13% revenue growth annually Presentation and webcast at 43 rd Annual J.P. Morgan Healthcare Conference today, Wednesday, January 15, at 1:30 p.m. PT / 4:30 p.m. ET “We ...

NeoGenomics (NASDAQ:NEO) has observed the following analyst ratings within the last quarter: In the last 3 months, 4 analysts have offered 12-month price targets for NeoGenomics. The company has an ...

NeoGenomics is a small-cap provider of cancer genetics diagnostics. They boast one of the most comprehensive oncology-focused testing menus in the world to help physicians diagnose and treat cancer. I ...

Fort Myers-based cancer testing and research lab NeoGenomics expects to report double-digit revenue growth for 2025. However, it still anticipates losses.

NeoGenomics appointed Abhishek Jain to the role of chief financial officer, succeeding Jeff Sherman, who is set to retire from the position in March.

Management raised full-year 2025 revenue guidance to $747 million-$759 million, reflecting 13%-15% growth. Adjusted EBITDA guidance remains unchanged at $55 million-$58 million. Pathline is projected ...

FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today issued the following statement in response to inquiries: NeoGenomics has cleared ...

NeoGenomics Inc. Chief Executive Mark Mallon stepped down Monday as the health-testing company revealed that first-quarter financials will miss guidance and rescinded its forecast for the full year, ...

NeoGenomics (NEO), a Fort Myers-based cancer testing and research lab, surprised Wall Street Monday with higher-than-expected third-quarter revenue and break-even earnings per share. The company ...

Forbes contributors publish independent expert analyses and insights. #1 stock picker for 51 straight months on SumZero. AI is my edge. The Most Attractive Stocks (+2.2%) underperformed the S&P 500 ...